報告

Ceritinib was the first of the 2nd generation TKIs developed by Novartis.  The recommended dose is 750mg daily. A small number of patients will still be taking Ceritinib. Alectinib was approved in August 2018 and this became the preferred drug for newly diagnosed patients.